Table of Contents 2
List of Tables 5
List of Figures 5
Compugen Ltd. Spshot 6
Compugen Ltd. Overview 6
Key Information 6
Key Facts 6
Compugen Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Compugen Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combition Treatment Modalities 13
Compugen Ltd. - Pipeline Products Glance 14
Compugen Ltd. - Early Stage Pipeline Products 14
Preclinical Products/Combition Treatment Modalities 14
Discovery Products/Combition Treatment Modalities 15
Compugen Ltd. - Drug Profiles 16
CGEN-15001 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CGEN-15021 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CGEN-15031 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CGEN-15051 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CGEN-15091 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CGEN-25009 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CGEN-856S 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclol Antibody to Inhibit CGEN-15049 for Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclol Antibody to Inhibit CGEN-15052 for Oncology 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclol Antibody to Inhibit CGEN-15092 for Multiple Sclerosis 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclol Antibody 1 to Inhibit CGEN-15029 for Oncology 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclol Antibody 2 to Target B7/CD28 for Oncology 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclol Antibody 3 to Target B7/CD28 for Oncology 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclol Antibody 4 to Target B7/CD28 for Oncology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Monoclol Antibody 5 to Target B7/CD28 for Oncology 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclol Antibody Conjugate 2 for Oncology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclol Antibody Conjugates 1 for Oncology 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclol Antibody for Cancer 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclol Antibody to Inhibit CGEN-15027 for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclol Antibody to Target CGEN-928 for Multiple Myeloma 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Compugen Ltd. - Pipeline Alysis 38
Compugen Ltd. - Pipeline Products by Target 38
Compugen Ltd. - Pipeline Products by Molecule Type 39
Compugen Ltd. - Pipeline Products by Mechanism of Action 40
Compugen Ltd. - Recent Pipeline Updates 41
Compugen Ltd. - Dormant Projects 45
Compugen Ltd. - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48